Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2022; 10(5): 1716-1722
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1716
Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
Jie Zhang, Mei-Hong Liu, Xue Gao, Chang Dong, Yan-Xia Li
Jie Zhang, Mei-Hong Liu, Chang Dong, Yan-Xia Li, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
Xue Gao, Department of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
Author contributions: Dong C and Zhang J reviewed the literature and contributed to manuscript drafting; Liu MH performed the collection and interpretation of the clinical data and material; Gao X analyzed and interpreted the pathological findings; Li YX was responsible for the revision of the manuscript for important intellectual content; all authors contributed to the manuscript and approved the final version to be submitted.
Supported by the Dalian Municipal Science and Technology Innovation Foundation, No. 2020JJ27SN072.
Informed consent statement: Informed written consent was obtained from the patient’s proxy for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work nonnon-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang Dong, MD, Associate Chief Physician, Associate Professor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Xigang District, Dalian 116011, Liaoning Province, China. dongchang8793@163.com
Received: October 11, 2021
Peer-review started: October 11, 2021
First decision: November 7, 2021
Revised: December 18, 2021
Accepted: January 5, 2022
Article in press: January 5, 2022
Published online: February 16, 2022
Processing time: 122 Days and 17.8 Hours
Core Tip

Core Tip: Vedolizumab is the treatment of choice for patients with moderate-to-severe ulcerative colitis who are refractory to tumor necrosis factor antagonists. However, some rare but potentially lethal drug-associated adverse effects warrant pharmacovigilance. We present a case of new-onset diffuse parenchymal lung disease development under treatment with vedolizumab in a patient with ulcerative colitis. After two doses of vedolizumab, he developed persistent fever, progressively worsening dyspnea and eventually died of respiratory failure. The patient was eventually diagnosed with vedolizumab-related interstitial lung disease, in spite of the few case reports found after reviewing the literature. We aim to raise gastroenterologists’ and pulmonologists’ vigilance to this uncommon adverse event.